上海招聘

[RESPONSIBILITIES]

1. 负责公司产品招投标支持 Support Product Bidding

2. 各地招标信息的收集，招标进展及招标结果的整理、汇总、上报及归档 Collect Bidding information, monitor bidding process and
track status reports

3. 销售数据统计核对 Gather and verify sales data

4. 提供各类销售数据的统计分析报告 Analyst sales data and prepare sales reports

5. 负责商务部的各项后勤工作 Back office support for all commercial communications


[REQUIREMENTS]

1. 从事医药商务或商务相关领域1年以上的工作经历，大专以上学历，医学或药学相关专业为佳（30岁以下）1 year or above working experience in commercial work for healthcare industry; college or above with medical related qualifications

2. 具有良好的观察和分析能力，工作认真仔细，学习能力强，责任心及执行力强 Good analytical skill, willing to learn and good accountability and ability to complete tasks timely and effectively

3. 良好的团队合作精神 Good teamwork

4. 良好的英语读写能力 Good written English skill (no need spoken English)

5. 优秀应届生亦可考虑 Fresh graduate also considered

Mallinckrodt, the Pharmaceuticals business of Covidien, is a vertically integrated leader in providing products used in diagnostic procedures and in the treatment of pain and related conditions. We are the largest U.S. supplier, by prescription, of opioid pain medications and a leading manufacturer of active pharmaceutical ingredients. We are also the largest global supplier of the medical isotope technetium-99m and an industry leader in radiopharmaceuticals, contrast media, and delivery systems. Mallinckrodt encompasses more than 5,500 dedicated employees around the globe, all focused on our core values of quality, integrity and service to meet the needs of patients globally. Please visit www.mallinckrodt.com to learn more about our business.

Established as G. Mallinckrodt & Company in 1867, the $2 billion St. Louis-based business was acquired by Tyco International in 2000. In 2007, Tyco spun off its healthcare business into Covidien, a leading global healthcare products company. On December 15, 2011, Covidien announced plans to spin off Mallinckrodt as a standalone public company. On February 1, 2013, Mallinckrodt submitted the initial filing of a Form 10 Registration Statement with the U.S. Securities and Exchange Commission. Covidien expects to complete the spin-off by mid-2013.

Mallinckrodt's mission is to reveal and relieve disease for a healthier world, and our vision expands on our mission - a world made healthier by building on our heritage of distinctive capabilities to provide patients with pharmaceuticals that reveal and relieve disease.